Selank 50mg — Vial Spec, Reconstitution Math & COA
A 50mg Selank vial provides a high-yield lyophilized format designed specifically for multi-plate cellular assays and high-throughput preclinical research protocols. This technical guide outlines exact solvent calculations, stability protocols, analytical verification metrics, and aliquot strategies for handling high-mass peptide vials. Researchers can evaluate lot-specific purity data or cross-reference smaller inventory formats to ensure absolute experimental reproducibility.
Quick answer
A 50mg Selank vial provides a high-yield lyophilized format designed specifically for multi-plate cellular assays and high-throughput preclinical research protocols. This technical guide outlines exact solvent calculations, stability protocols, analytical verification metrics, and aliquot strategies for handling high-mass peptide vials. Researchers can evaluate lot-specific purity data or cross-reference smaller inventory formats to ensure absolute experimental reproducibility.
Key takeaways
- A 50mg vial of [Selank](/research-peptides/selank) contains fifty milligrams of pure, highly purified synthetic heptapeptide (sequence: Thr-Lys-Pro-Arg-Pro-Gly-Pro) supplied as a freeze-dried (lyophilized) cake or powder.
- Reconstituting a high-mass 50mg vial requires precise volumetric planning to achieve target molarity or milligram-per-milliliter concentrations without exceeding vial headspace or solvent solubility limits.
- Once a 50mg vial of [Selank](/research-peptides/selank) is reconstituted into a liquid state, its peptide backbone becomes significantly more vulnerable to thermal degradation, bacterial proliferation, and hydrolysis compared to its dry lyophilized state.
- Every batch of [Selank](/research-peptides/selank) produced for PX1 Research undergoes rigorous, independent quality control testing in ISO 17025 accredited analytical laboratories.
High-Mass Lyophilized Format: What a Selank 50mg Vial Delivers
A 50mg vial of Selank contains fifty milligrams of pure, highly purified synthetic heptapeptide (sequence: Thr-Lys-Pro-Arg-Pro-Gly-Pro) supplied as a freeze-dried (lyophilized) cake or powder. Selank is a synthetic analog of the naturally occurring immunomodulatory peptide tuftsin, elongated at the C-terminus with a Pro-Gly-Pro tripeptide sequence to resist enzymatic degradation. In high-density experimental setups, a 50mg mass mass fill serves primary research requirements where large volumetric stocks are necessary to maintain standardized baseline concentrations across extensive microplate series or prolonged animal model cohorts.
Primary users of the 50mg vial format include contract research organizations (CROs), academic neuroscience facilities, and high-throughput screening platforms conducting multi-target receptor binding assays or gene expression profiling. Utilizing a single 50mg vial for an entire assay series eliminates inter-vial reconstitution variance, ensuring that every micro-well or experimental group receives an identical chemical treatment from the exact same manufacturing lot.
Please note that PX1 Research maintains flexible catalog inventory to serve diverse laboratory sizes. While high-volume requests and dedicated wholesale lab accounts frequently utilize custom 50mg fills, standard single-unit stock is commonly distributed in the Selank 10mg format. This allows researchers requiring smaller working volumes to prevent waste and avoid unnecessary solution storage.
Reconstitution Mathematics & Concentration Calculations for 50mg Selank
Reconstituting a high-mass 50mg vial requires precise volumetric planning to achieve target molarity or milligram-per-milliliter concentrations without exceeding vial headspace or solvent solubility limits. Selank exhibits excellent aqueous solubility, dissolving rapidly in sterile bacteriostatic water, standard sterile 0.9% sodium chloride (saline), or phosphate-buffered saline (PBS). Because 50mg represents a substantial mass of peptide, researchers must choose their diluent volume carefully based on pipetting precision and microplate well capacity.
To achieve standard working concentrations, use the following diluent volumetric ratios: Adding 1.0 mL of solvent to a 50mg vial yields a stock concentration of 50.0 mg/mL (50.0 µg/µL). Adding 2.0 mL yields 25.0 mg/mL (25.0 µg/µL). Adding 2.5 mL yields 20.0 mg/mL (20.0 µg/µL). Adding 5.0 mL yields 10.0 mg/mL (10.0 µg/µL). Adding 10.0 mL yields 5.0 mg/mL (5.0 µg/µL). When solubilizing, the solvent should be introduced gently along the interior glass wall rather than sprayed directly onto the lyophilized cake.
To prevent mechanical shear stress on the peptide backbone, never vortex the vial aggressively. Instead, allow the solvent to saturate the cake naturally for 2 to 3 minutes, followed by gentle hand-swirling until the solution is completely clear and free of particulates. Laboratory technicians calculating custom molarities for in vitro binding studies are encouraged to utilize our interactive peptide reconstitution calculator to quickly verify micro-liter aliquot requirements.
Aliquot Strategy & Freeze-Thaw Prevention Protocols
Once a 50mg vial of Selank is reconstituted into a liquid state, its peptide backbone becomes significantly more vulnerable to thermal degradation, bacterial proliferation, and hydrolysis compared to its dry lyophilized state. Repeated freezing and thawing of a single stock container creates ice crystal micro-environments that shear peptide bonds, leading to loss of bioactivity and reduced purity across experimental runs.
To maximize stability, laboratories should immediately execute a sterile aliquoting protocol following complete dissolution. Solubilized stock should be pipetted into single-use, low-binding polypropylene microcentrifuge tubes in volumes matched to daily assay requirements (e.g., 50 µL to 200 µL per aliquot). Polypropylene or low-retention fluoropolymer tubes are mandatory, as standard glass or untreated plastic can non-specifically adsorb hydrophobic peptide sequences out of solution over time.
Working aliquots intended for use within 24 to 48 hours may be maintained at 2°C to 8°C. All remaining stock aliquots must be immediately flash-frozen and stored at -20°C or -80°C. Avoid storing reconstituted peptide stock in frost-free commercial freezers, as their automated heating cycles cause temperature fluctuations that prematurely degrade the compound.
Analytical Verification & Lot-Matched COA Standards
Every batch of Selank produced for PX1 Research undergoes rigorous, independent quality control testing in ISO 17025 accredited analytical laboratories. High-mass 50mg fills demand non-negotiable purity parameters to ensure that high concentrations of peptide do not introduce unquantified synthetic impurities or residual solvents into sensitive biological assays.
Analytical verification relies on two primary physical testing modalities: High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry (MS). HPLC analysis measures chromatographic purity, ensuring that the target sequence comprises ≥98.0% of the total peptide area with minimal truncated or incomplete synthesis side-products. Mass Spectrometry verifies absolute identity by confirming the exact target molecular weight (751.9 g/mol) matches the theoretical molecular mass of the sequence.
Additionally, every lot undergoes Limulus Amebocyte Lysate (LAL) testing to confirm endotoxin levels remain below strict threshold limits (<0.01 EU/µg), preventing endotoxin-induced inflammatory artifacting in cell cultures or animal models. Laboratory managers can independently view and download full batch analytical reports prior to unsealing materials via our centralized lot-matched COA lookup portal.
Molecular Mechanism & Preclinical Literature Summary
Preclinical investigation into Selank centers on its dual capacity as a neurotrophic modulator and a regulator of endogenous neuropeptide degradation. Designed as a synthetic stable derivative of the endogenous immunomodulatory peptide tuftsin, Selank incorporates a C-terminal Pro-Gly-Pro extension. Preclinical rodent models demonstrate that this structural modification protects the molecule from rapid cleavage by circulating plasma carboxypeptidases and aminopeptidases, extending its metabolic half-life significantly compared to native tuftsin.
In vitro and animal study data indicate that Selank modulates gene expression related to neuroplasticity and neurotransmission. Research shows that Selank administration upregulates messenger RNA (mRNA) expression of Brain-Derived Neurotrophic Factor (BDNF) and its primary tyrosine kinase receptor, TrkB, within hippocampal and cortical tissue preparations. BDNF elevation is associated in preclinical models with enhanced synaptic plasticity, dendritic spine density, and neuroprotective resilience against oxidative stress.
Furthermore, electrophysiological assays reveal that Selank acts as an allosteric modulator of the GABA-A receptor complex. Preclinical assays indicate that while Selank does not bind directly to the classical benzodiazepine binding site, it alters affinity for gamma-aminobutyric acid, modulating inhibitory chloride ion currents. For expanded scientific literature, mechanism diagrams, and citations, explore our dedicated preclinical research library.
Comparative Analysis: Selank, Semax, and N-Acetyl Selank Amidate
When designing neurological or cell signaling assays, researchers frequently evaluate multiple heptapeptide derivatives within the same research class to contrast receptor selectivity and structural stability. The primary baseline compound, Selank, provides an un-modified synthetic tuftsin analog ideal for establishing core GABAergic and neurotrophic baseline measurements in standard physiological buffers.
In contrast, researchers studying melanocortin signaling pathways often compare Selank against Semax, an ACTH(4-10) heptapeptide derivative (Met-Glu-His-Phe-Pro-Gly-Pro). While Selank primarily impacts GABAergic tone and enkephalinase inhibition, Semax acts predominantly on melanocortin receptors (MC4R/MC5R) and exerts distinct effects on striatal dopamine and serotonin turnover in preclinical models.
For studies requiring extended enzymatic resilience in harsh enzymatic environments or tissue homogenates, modified analogs such as N-Acetyl Selank Amidate are frequently selected. The addition of an N-terminal acetyl group and C-terminal amidation neutralizes terminal charges, drastically reducing susceptibility to exopeptidases and altering lipophilicity, which directly impacts cellular uptake kinetics in microvascular cell culture models.
Storage and Handling Protocols for Lyophilized Powder
Proper physical storage conditions are critical for preserving the chemical integrity of a 50mg Selank vial over extended timeframes. Unreconstituted lyophilized Selank is stable at room temperature (15°C to 25°C) for short periods during transit; however, upon arrival in the laboratory, vials should be immediately transferred to long-term cold storage.
For optimal shelf-life, unopened lyophilized vials should be maintained at -20°C for up to 24 months, or at -80°C for ultra-long-term archiving up to 36 months. Vials must be protected from ambient moisture and direct light exposure. Solid lyophilized peptide is hygroscopic; exposing a cold, opened vial to humid laboratory air leads to rapid atmospheric water condensation inside the container, accelerating peptide hydrolysis.
To prevent moisture condensation during reconstitution, always allow frozen lyophilized vials to equilibrate to ambient room temperature (approximately 20–30 minutes) on the laboratory bench prior to removing the aluminum flip-off cap and puncturing the rubber stopper with a solvent needle.
Selecting Vial Sizes: 10mg vs. 50mg Format Selection
Choosing between a 10mg vial and a 50mg vial format depends directly on experimental design, protocol scale, and storage capabilities. Smaller 10mg vials represent the optimal selection for pilot studies, low-throughput cell culture plates, or sporadic analytical testing where solubilized solutions will be completely consumed within 24 to 48 hours.
Conversely, selecting a 50mg mass fill is ideal for automated robotics platforms, high-content screening (HCS), or multi-animal longitudinal studies where preparing fresh stock from multiple small vials introduces volumetric and mass-measurement variables into the protocol. Utilizing a single 50mg batch guarantees absolute chemical consistency across thousands of assay wells.
Researchers seeking to evaluate all available fill sizes, sequence variants, or related central nervous system research compounds can review our complete inventory via the all peptides catalog to align container formats with their specific laboratory apparatus.
PX1 Quality Assurance and Domestic Supply Logistics
PX1 Research operates strictly as a B2B research supplier committed to analytical rigor and transparent supply chain operations. All peptide compounds offered by PX1 Research are manufactured in state-of-the-art facilities compliant with Good Manufacturing Practice (GMP) standards, ensuring exact amino acid sequence fidelity, consistent solid-state lyophilization, and absolute purity across every manufacturing lot.
We recognize that research schedules depend on fast, reliable fulfillment. All orders placed Monday through Friday before cut-off times are processed with same-day shipping directly from our primary distribution centers located in California and Arizona. Shipments are packed using insulated secondary packaging to protect structural integrity against extreme ambient temperatures during transit.
Every shipped container includes lot-matched tracking identifiers that map directly to online analytical certificates. PX1 Research exclusively supplies chemical materials for in vitro, cellular, and preclinical laboratory research use only—never for human, clinical, or veterinary applications.
Frequently Asked Questions
What exact chemical compound is contained in a Selank 50mg vial?
A Selank 50mg vial contains 50 milligrams of pure lyophilized synthetic heptapeptide with the chemical sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro (Molecular Mass: 751.9 g/mol). It is supplied for in vitro and laboratory research applications only.
Why would a laboratory select a 50mg Selank vial instead of smaller sizes?
High-throughput screening setups, automated liquid handlers, and multi-plate cell culture assays select 50mg vials to prepare large, uniform stock solutions from a single lot, eliminating inter-vial variance across long-term protocols.
How much solvent should be added to reconstitute 50mg of Selank?
Solvent volume depends on desired target concentration. Adding 1.0 mL of diluent creates a 50 mg/mL (50 µg/µL) concentration, while 5.0 mL creates a 10 mg/mL (10 µg/µL) stock concentration. Use the PX1 online reconstitution calculator for exact dilution protocols.
Does PX1 stock 50mg Selank vials continuously for immediate dispatch?
Standard catalog inventory frequently features the 10mg vial size to minimize freeze-thaw risk for standard bench protocols. High-mass 50mg formats are manufactured for bulk, CRO, and custom wholesale laboratory accounts.
How should reconstituted Selank stock be stored to prevent degradation?
Reconstituted Selank must be immediately aliquoted into single-use polypropylene tubes to prevent surface absorption and freeze-thaw breakdown. Store working aliquots at -20°C or -80°C in non-frost-free freezers.
What analytical purity level is guaranteed for PX1 Selank batches?
PX1 Research guarantees a minimum analytical purity of ≥98.0% as verified by HPLC and Mass Spectrometry, with endotoxin levels strictly controlled below <0.01 EU/µg.
How can I obtain the lot-specific Certificate of Analysis (COA)?
Researchers can enter their batch lot number into the PX1 COA lookup portal to view and download full HPLC chromatograms, MS spectra, and endotoxin assay reports.
Can Selank be dissolved in standard phosphate-buffered saline (PBS)?
Yes, Selank is highly water-soluble and dissolves readily in sterile PBS, sterile 0.9% saline, or sterile bacteriostatic water depending on cell culture assay compatibility.
Related pages
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.